Replies to post #795112 on NorthWest Biotherapeutics Inc (NWBO)

[Gus1212]

Smitty - What is a reasonable SP after approval in your view.
Did you place one out that you can refer to?

I would be happy with any price until volume started to ramp up.
Thanks for all your views

[VikingInvest]

Smitty,

Your post is not inherently untrue. There are many stages that will need to be completed before this stock will take off to the moon. I think the people thinking that the SP will hit $10-20 will be dissappointed when approval happens. I have been wrong before, and could easily be wrong on this too. That being said, I do think that we will see a nice upward movement that should challenge at least the recent highs in the low $2's and quite possibly higher. The big guns might not add the stock to their portfolio while we are still on the OTC, but there will be plenty of smaller funds that will build strong positions in the stock. The currently shorting HF's might even turn around and become investors as they should know the potential of this company upon approval. I, personally, know of a few people in the investment community who will likely build positions upon approval. Approval will validate the science and as you mentioned, post new questions to the company, that will have to be answered post approval. Some of us, who follow the company close, feel that they should be in a good position to answer these questions, such as Flaskworks approval. With approval from MHRA in hand, it should not be difficult for them to get "in bed" with big pharma in regard to their upcoming FDA application process. I think, as an investment thesis, There will be plenty of people who can see the potential of the science and the potential platform it can grow into, to take larger positions. The potential valuation is hard to determine, but looking at the price some of the BP's have paid for other smaller companies with much less potential than NWBO, there is no reason to think that with time and progress NWBO could challenge some of these prices, which will still make it an attractive buy at a valuation under $10B (roughly $5-6 per share). Post approval, the risk factor will also become much less of a factor.

I understand that some people on this board are deep in the water with this company, but situationally, a $2.59 SP post approval will be a 10x from today, which is a sizeable move for any stock. Again, I am not saying or predicting any SP upon approval, just that the move upwards will be in phases and I, for one, will be patient and look at approval as the first stage in the potential rocket that is NWBO.

GL to all investors.

[GoodGuyBill]

First you said "massive revenues" were a prerequisite before wall-street engage/invest in NWBO. Now you are saying "until these things happen".

My point is "massive revenues" are not necessary for wall-street to get on the NWBO train in a substantial way. MHRA approval AND big pharma multiple partnerships would be a clear indication of minimized risks. Furthermore, the fact that DCVax is the best or only game in town for all cancer tumors, NWBO has dendritic cells on lock-down with patents galore and ,via Eden, can scale infinitely, lowers risk even more (even if you hold the view that DCVax agnostic designation will be achieved later). NWBO will NOT need massive revenues before wall-street invests significant $$$.